Abbott recently said its Proclaim DRG Neurostimulator System, which stimulates dorsal root ganglion (DRG) and eases pain in patients with complex regional pain syndrome (CRPS) of the lower limbs, .has been launched in the U.S.
"Both clinical and real world data have shown that DRG stimulation produces long-term, meaningful pain relief for patients with complex regional pain syndromes – like those resulting after total knee arthroplasty, foot surgery or hernia surgery," Dr. Timothy Deer, an interventional pain physician, president and chief executive officer of the Spine and Nerve Center of the Virginias in Charleston, West Virginia, and co-principal investigator of the ACCURATE study, said in the Abbot release .
One in four people across the globe suffers from chronic pain; the condition drives up physician office visits and drives down quality of life. CRPS is one type of chronic pain and is difficult to treat due to its complex intensity and location on the body, the release said.
The Proclaim DRG system is an upgrade from Abbot's previous systems and will help target this complex chronic pain, the release said.
"The ability to offer DRG stimulation on the Proclaim platform is a very exciting advancement for those of us who treat patients with these debilitating conditions and want to provide relief from hard-to-treat neuropathic conditions,” Deer said in the release.
